

Jack Cook

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1777978/publications.pdf>

Version: 2024-02-01

18
papers

304
citations

840776

11
h-index

888059

17
g-index

23
all docs

23
docs citations

23
times ranked

368
citing authors

#	ARTICLE	IF	CITATIONS
1	Roadmap to 2030 for Drug Evaluation in Older Adults. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 210-223.	4.7	19
2	Clinical Relevance of Hepatic and Renal P-gp/BCRP Inhibition of Drugs: An International Transporter Consortium Perspective. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 573-592.	4.7	15
3	Drug Dosing Recommendations for All Patients: A Roadmap for Change. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 65-72.	4.7	32
4	Regarding Combined Pediatric and Adult Trials Submitted to the US Food and Drug Administration 2012-2018. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1181-1181.	4.7	2
5	The Weight of Evidence From Electrophysiology, Observational, and Cardiovascular End Point Studies Demonstrates the Safety of Azithromycin. <i>Clinical and Translational Science</i> , 2021, 14, 106-112.	3.1	2
6	Response to "Personalized Dosing = Approved Wide Dose Ranges + Dose Titration". <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 568-568.	4.7	0
7	Industrial Perspective on the Benefits Realized From the FDA's Model-Informed Drug Development Paired Meeting Pilot Program. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1172-1175.	4.7	15
8	To blind or not to blind first in human and exploratory clinical trials: Acceleration of development vs. risk of bias. <i>Clinical and Translational Science</i> , 2021, , .	3.1	3
9	ICH M9 Guideline in Development on Biopharmaceutics Classification System-Based Biowaivers: An Industrial Perspective from the IQ Consortium. <i>Molecular Pharmaceutics</i> , 2020, 17, 361-372.	4.6	13
10	Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 1135-1149.	4.7	25
11	A Real-World Evidence Framework for Optimizing Dosing in All Patients With COVID-19. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 921-923.	4.7	8
12	Utility of Model-Based Approaches for Informing Dosing Recommendations in Specific Populations: Report From the Public AAPS Workshop. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 105-109.	2.0	12
13	A proposal for scientific framework enabling specific population drug dosing recommendations. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 1073-1078.	2.0	39
14	A randomized, open-label 3-way crossover study to investigate the relative bioavailability and bioequivalence of crushed sildenafil 20-mg tablets mixed with apple sauce, extemporaneously prepared suspension (EP), and intact sildenafil 20-mg tablets in healthy volunteers under fasting conditions. <i>Clinical Pharmacology in Drug Development</i> , 2015, 4, 74-80.	1.6	14
15	Impact of Discordance Among Regulations for Biopharmaceutics Classification System-Based Waivers of Clinical Bioequivalence Studies. <i>Dissolution Technologies</i> , 2015, 22, 6-10.	0.6	3
16	Quality-by-Design: Are We There Yet?. <i>AAPS PharmSciTech</i> , 2014, 15, 140-148.	3.3	23
17	A Randomized, Open-Label, 3-Way Crossover Study to Demonstrate Bioequivalence of Sildenafil Powder for Oral Suspension With Tablets Used Commercially and in Clinical Studies for the Treatment of Pulmonary Arterial Hypertension. <i>Clinical Pharmacology in Drug Development</i> , 2012, 1, 152-157.	1.6	4
18	Application of the Biopharmaceutical Classification System in Clinical Drug Development—An Industrial View. <i>AAPS Journal</i> , 2008, 10, 306-310.	4.4	73